Vascular Compliance After ABSORB Implantation scaffold implantation may potentially disappear in the longterm once the scaffold is completely bioresorbed.
The aim of the present analysis was to investigate the vascular compliance of the coronary segments treated with the bioresorbable scaffold and the adjacent proximal and distal edges, by measuring: (1) the changes in compliance immediately after ABSORB BVS implantation and at 6-, 12-and 24-month follow-up; and (2) the compliance mismatch between these 3 segments at the various time points.
Methods

Study Population
The ABSORB trial includes the ABSORB Cohorts A and B trials. In brief, the ABSORB Cohort A trial (NCT00300131) enrolled 30 patients with a diagnosis of stable or unstable angina or silent ischemia. All treated lesions were single and de novo in a native coronary artery of 3.0 mm diameter, shorter than 8 mm for the 12-mm scaffold and shorter than 14 mm for the 18-mm scaffold, with a diameter stenosis ≥50% and <100%, and with a Thrombolysis in Myocardial Infarction flow grade ≥1. Major exclusion criteria were acute myocardial infarction, unstable arrhythmias or left ventricular ejection fraction <30%, restenotic lesions, lesions located in the left main coronary artery, lesions involving an epicardial side branch ≥2 mm in diameter by visual assessment, and the presence of thrombus or other clinically significant stenosis in the target vessel. All lesions were treated by implantation of ABSORB BVS firstgeneration scaffold (Generation 1.0) and invasively imaged at 6-and 24-month follow-up. The ABSORB Cohort B trial (NCT00856856) enrolled 101 patients with the same clinical profile and lesion type, divided into 2 groups according to the timeline of invasive follow-up: ABSORB Cohort B1 with invasive imaging at 6 and 24 months; ABSORB Cohort B2 with the same invasive imaging at 12 and 36 months. The 12-month follow-up has been reported. 5 All lesions were treated by implantation of an ABSORB BVS second generation scaffold (Generation 1.1) (3.0×18 mm). 6 The ethics committee at each participating institution approved the protocol and each patient gave written informed consent before inclusion.
Study Device
The ABSORB BVS scaffold (Abbott Vascular, Santa Clara, CA, USA) consists of a polymer backbone of poly-L lactide (PLLA) coated with a thin layer of a 1:1 mixture of poly-D, L-lactide (PDLLA) polymer, and the antiproliferative drug, everolimus, to form an amorphous drug-eluting coating matrix containing 100 μg of everolimus/cm 2 of scaffold. The details of the device have been previously described. 7-11 The AB-SORB Cohort A and Cohort B trials evaluated the ABSORB BVS scaffold generations 1.0 and 1.1, respectively. 12, 13 The ABSORB BVS scaffold 1.1 has a smaller maximum circular unsupported surface area compared to 1.0, with the struts arranged as in-phase zigzag hoops linked together by 3 longitu- dinal links, similar to the XIENCE V design. 8, 14 No differences in polymeric material, drug dose, drug release kinetics or strut thickness exist between the 2 generations. Of note is that changes implemented in the manufacture of ABSORB BVS 1.1 resulted in more prolonged luminal support post-implantation. 6,15,16
Study Procedure and Intravascular Ultrasound (IVUS) Acquisition/Analysis Target lesions were treated using standard interventional techniques with mandatory pre-dilation. Post-dilation with a balloon that was shorter than the implanted scaffold was allowed at the operator's discretion up to the prescribed maximal postdilation diameter.
IVUS palpography analyses were performed using the Eagle Eye 20 MHz catheter (Volcano Corp, Rancho Cordova, CA, USA) with an automated continuous pullback (0.5 mm/s, 30 frames/s) at the level of the scaffolded and adjacent segments, with simultaneous recordings of the electrocardiogram and aortic pressure, at various follow-up time points.
IVUS Palpography Acquisition and Analysis
IVUS palpography is a technique that allows for the assessment of local mechanical tissue properties. The underlying principle is that at defined pressure differences soft tissue (eg, lipid-rich) components deform more than hard tissue components (eg, fibrous-calcified). [17] [18] [19] In coronary arteries the tissue of interest is the vessel wall, whereas blood pressure, with its physiological changes during the heart cycle, is used as the excitation force. Radiofrequency data obtained at different pressure levels are compared to determine the local tissue deformation. The strain value is normalized to a pressure difference of 2.5 mmHg per frame: this allows the construction of a "strain" image in which hard (low strain/compliance) and soft (high strain/compliance) values range between 0% and 2%. 17 In postmortem coronary arteries the sensitivity and specificity of palpography to detect high strain values have previously been reported as 88% and 89%, respectively. 18 Digital radiofrequency data were acquired using a customdesigned workstation and subsequently stored on a DVD for sending to the imaging core laboratory for offline analyses (Cardialysis, Rotterdam, The Netherlands). Both the scaffolded and the 5-mm proximal and distal segments were analyzed. 20 Local strain was calculated from the gated radiofrequency traces using cross-correlation analyses, displayed and color-coded from blue (for 0% strain) to yellow (for 2% strain) Continuous variables are expressed as mean ± SD. MI, myocardial infarction; NA, not applicable; RVD, reference vessel diameter; MLD, minimum lumen diameter; ACEI, angiotensin-converting enzyme inhibitor; SD, standard deviation. Vascular Compliance After ABSORB Implantation via red as previously described. 19 Strain values were assigned a Rotterdam classification (ROC) score ranging from I to IV (ROC I, 0-0.5%; ROC II, 0.6-<0.9%; ROC III, 0.9-1.2%; ROC IV, >1.2%). 21 A region was defined as high strain when it had ROC III-IV that spanned an arc of at least 12° at the surface of a plaque (identified on the IVUS recording), as previously reported. The highest value of strain in the cross-section was taken as the strain level of the site. 21 The compliance of each segment was calculated per segment (proximal edge, scaffold segment and distal edge) and defined as the mean of the maximum strain values per crosssection in ROC I/II/III/IV sites, expressed as ROC/mm. 22, 23 Ideally, the absence of a mismatch is the absence of difference in compliance along the vessel wall. For the purpose of the present analysis, mismatch was defined as statistically significant differences in compliance between the 3 segments analyzed on a paired basis, using a statistical test for trend ( Figure 1 ).
Statistical Analysis
Categorical variables are presented using frequencies and percentages. Continuous variables are presented with mean and standard deviations or median and interquartile ranges, according to their distribution. Analyses of normality of the continuous variables were performed with the Kolmogorov-Smirnov test. Changes in compliance between various time points were evaluated by means of paired Wilcoxon signed rank test. Differences in compliance between the 3 segments analyzed (scaffold, proximal and distal edges) at each time point were evaluated by the paired Friedman test. Comparison between 2 groups was performed with the Mann-Whitney test. A 2-sided P-value <0.05 indicated statistical significance. Statistical analyses were performed with SPSS 18.0 software (SPSS, Chicago, IL, USA). (Table 1) A total of 83 patients from the ABSORB Cohort A and B trials underwent palpography investigations (30 and 53 patients from ABSORB Cohort A and Cohort B, respectively). Specifically, palpography analyses were performed in 27 patients pre-scaffold implantation (13 and 14 from ABSORB Cohort A and Cohort B), 71 patients post-scaffold implantation (27 and 44 from ABSORB Cohort A and Cohort B), 42 patients at 6 months (27 and 15 from ABSORB Cohort A and Cohort B), 26 patients at 12 months and in 21 patients at 24 months.
Results
Baseline Clinical Characteristics
Palpography analyses were completed for all 3 segments (scaffold, proximal and distal segments) in 14 patients at prescaffold implantation (5 and 9 from ABSORB Cohort A and Cohort B), 35 patients post-implantation (14 and 11 from AB-SORB Cohort A and Cohort B), 27 patients at 6 months (16 and 11 from ABSORB Cohort A and ABSORB Cohort B), 11 patients at 12 months and 14 patients at 24 months. 
Modification in Vascular Compliance From Pre- to PostScaffold Implantation (Figure 2)
After scaffold implantation a significant decrease in compliance in the scaffolded segment was evident with no modification in the proximal/distal edges compliance. Of note, a trend towards a reduction in compliance was evident in the distal edge ( Figure 3 ). The modifications in compliance after scaffold implantation did not significantly differ between ABSORB Cohort A and Cohort B in the 3 segments (scaffolded segment P=0.820; proximal edge P=0.310; distal edge P=0.606).
A mismatch in compliance tended to be present immediately after scaffold implantation (Figure 4 ).
Modification in Vascular Compliance During Follow-up (Tables 2,3)
In ABSORB Cohort A there was a significant increase in the compliance of the scaffolded segment at 6 and 24 months compared to post-implantation. Conversely, in ABSORB Cohort B no changes in compliance of the scaffolded segment were evident at either 6 (P<0.001 as compared to ABSORB Cohort A) or 12 months, compared to post-implantation. No other significant changes were found at the proximal/distal edges in either ABSORB Cohort A or B at the various time points.
At the various follow-up time points, no mismatch in compliance was found either in Cohort A (6 months=proximal edge 0. 
Discussion
The major findings of the present analysis are: (1) scaffolding of a diseased vessel wall by an ABSORB BVS significantly reduces its compliance, with the compliance of the segment immediately distal to the device tending also to be reduced; (2) the mismatch in compliance that is present immediately after scaffold implantation disappears in the short-to midterm; (3) the prolonged duration of mechanical support of the ABSORB BVS generation 1.1, compared to BVS 1.0, is responsible for the differing changes in vascular compliance in the scaffold segment between the 2 devices at 6 months.
Compliance and Pulsatility of the Scaffolded Segment
Palpography is a technique of assessing the elastic properties of the coronary vessel wall; in particular, it analyzes the ability of the artery to be distended, providing a measurement of its compliance. 17,19,24 Deployment of a stiff metallic stent over coronary plaque may mechanically reduce the local compliance of the coronary vessel wall. 25 This reduction may be further explained by the fact that the foreign scaffold material may partially interfere with the palpography measurements due to the artifactual acoustic properties of the stent struts themselves. 25 Figure 3 . Changes in compliance after scaffolding with an ABSORB BVS device. Strain value (ROC/mm) pre-and post-ABSORB scaffold implantation in paired patients for proximal edge (n=20 patients), scaffold segment (n=20 patients) and distal edge (n=14 patients). ROC: Rotterdam Classification. Vascular Compliance After ABSORB Implantation Implantation of an ABSORB BVS, made of polymeric material, reduces the local compliance of the scaffolded segment and possibly the acute vulnerability of the treated coronary plaque. 19,25 Nevertheless, with the first ABSORB Revision 1.0 at long term, an increase in compliance was observed in parallel with bioresorption of the scaffold. 9, 25 It is noteworthy that with the progressive disappearance of the polymeric scaffold, the vessel wall can recover a normal response to physiologic pulsatile cyclic strain and to shear stress; this positive interplay between cyclical strain and shear stress can be translated into chemical signals by cells with upregulation of the e-NOS gene, prostacyclin and metalloproteinases production, expression of anti-inflammatory genes, low permeability and low oxidative stress in the endothelial cells and in the smooth muscle cells. 26- 29 The presence of endothelial-dependent vasomotion in the vascular segment scaffolded by an ABSORB BVS device suggests that all these biological processes work appropriately. 5, 13 Conversely, cell signaling is altered in metallic scaffolded segments, where the vessel's distensibility is eliminated by metallic caging and it is exposed to static and non-pulsatile strain. [30] [31] [32] It should be also noted that the vessel wall compliance over time may be modulated differently according to the type of polymeric device implanted. The 2 generations of ABSORB BVS were compared at post-implantation and at 6-month follow-up. No differences in their ability to reduce vascular compliance immediately after implantation were found, confirming the absence of differences in acute mechanical properties, such as acute recoil, between the 2 BVS generations. 33 Nevertheless, at 6 months the compliance of the scaffolded segment Figure 4 . Compliance mismatch between the scaffold segment and the proximal/distal edges. Whereas there was not a compliance mismatch before scaffold implantation, it tended to be present after scaffold implantation, mainly due to the reduction in compliance in the scaffold segment. Each panel shows the patients with the analysis in all 3 segments available. Note that patients are not paired between the 2 graphs. BRUGALETTA S et al.
increased after ABSORB 1.0 implantation, whereas it tended to further decrease after ABSORB 1.1 implantation. These findings are in line with expectations: smaller maximum circular unsupported surface area and a slower rate of degradation of the generation 1.1 compared to 1.0 aim to improve and prolong the duration of lumen scaffolding and to avoid the "late recoil" phenomenon (scaffold area reduction over time), likely explaining the differing changes over time in compliance of the scaffolded segment between the 2 generations. 5,6,14-16
Compliance Mismatch Between the Scaffolded and Contiguous Segments
Local stiffness due to metallic stent implantation, in contrast to the compliance of the contiguous vascular segments, generates a compliance mismatch (Figures 1,2) . Vernhet et al previously showed that metallic stent implantation within the normal rabbit abdominal aorta causes a persistent increase in upstream compliance, while simultaneously abolishing compliance in the stented segment, creating a compliance mismatch. 34 Similar findings have been demonstrated in human carotid arteries after stenting. 35 It has also been shown that ring vortices with in-flow stagnation points and rapid variations of wall shear stress can form at the edges of the prosthesis. 3,26,36 All of these findings, in particular the increase in upstream compliance, have been related to the observation that late plaque rupture after stenting in human coronary arteries is more likely to occur at the stent inflow compared to elsewhere. 20 At variance with these metallic stent observations, ABSORB BVS implantation did not increase the compliance in the inflow segment, but conversely tended to decrease it in the outflow segment (Figure 3) . Normally, there is propagation of pressure waves along the vessel wall (the so-called Windkessel effect) and at sites where this process is interrupted (eg, side branches, stent/scaffold) there is a reflection of pressure waves with prevention of their propagation. 37 This may eventually reduce wall motion and compliance distally, explaining the changes observed in the present analysis in the segment distal to the scaffold. 38, 39 Although a compliance mismatch between the scaffolded and adjacent segments was demonstrated immediately after polymeric scaffold implantation, it disappeared at 6 months in contrast to metallic stents (Figure 2) . The abolition of a stepup compliance at the scaffold edges can theoretically lead to laminar flow, exposing the endothelial cells to a homogeneous shear stress, which can eventually result in atheroprotective and anti-restenosis effects. 20,26,39,40 Long-term data from the ABSORB B trial up to 3 years are awaited to confirm these findings.
Study Limitations
The major limitation of the present analysis is the small group of patients with paired palpography analysis at the various time points. This cohort of patients does, however, currently represent the sole set of available data on polymeric scaffold and vascular compliance. The lack of a control group testing a metallic stent is another limitation to fully interpreting the present findings; other investigators have, however, previously studied the phenomenon of mismatch compliance in vessel scaffolded with metal. 34, 35 
Conclusions
Scaffold implantation with an ABSORB BVS device transiently reduces the vascular distensibility of a treated coronary segment. In contrast to metallic stents, the created mismatch in compliance with the proximal and distal segments disappeared at mid-term due to the bioresorption and disappearance of the scaffold. Potential clinical benefits of these findings, related to restoration of vessel wall pulsatility and absence of mismatch, will require longer term clinical follow-up in a larger population.
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